A 3-month open label, national, quality-of-life, and safety study with pimecrolimus cream, 1 percent in children (age 2-12 years) with atopic dermatitis

Trial Profile

A 3-month open label, national, quality-of-life, and safety study with pimecrolimus cream, 1 percent in children (age 2-12 years) with atopic dermatitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2007

At a glance

  • Drugs Pimecrolimus (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top